CNR1 and obesity disorder: A recent clinical study was conducted involving patients with high-risk obesity who were treated with a new CB1R inverse agonist, INV-202 (25 mg per day), for 28 days to evaluate its clinical safety, tolerability, and pharmacokinetic and pharmacodynamic profile.